Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Solid Tumor : Relapsed or refractory solid tumors or brain tumors
This is a phase I study of a drug called tivantinib. Tivantinib is considered experimental because it has not been approved by the Food and Drug Administration (FDA) for use in children.
Participants will receive oral tivantinib twice daily. Participants in Part A will receive tivantinib capsules, and participants in Part B will receive tivantinib powder sprinkled on food. In addition, we will check blood levels of this drug and define side effects.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Wayne Furman, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
Referring or consulting physicians only: email@example.com
For all other inquiries about St. Jude Children's Research Hospital studies: firstname.lastname@example.org
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.